Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier
- PMID: 36456838
- DOI: 10.1007/s12602-022-10005-x
Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier
Abstract
Alcoholic liver disease (ALD) is a worldwide health threaten lack of effective treatment. Gut dysbiosis and concomitant augmented intestinal permeability are strongly implicated in the pathogenesis and progression of ALD. Research on the protective effect of probiotics on ALD is limited, and more effective intestinal microecological regulators and the related mechanisms still need to be further explored. In the present study, the protective effects and mechanisms of a compound probiotic against acute alcohol-induced liver injury in vivo were explod. It was showed that the compound probiotic ameliorated liver injury in acute ALD mice and stabilized the levels of ALT, AST, and TG in serum. The compound probiotic reversed acute alcohol-induced gut dysbiosis and maintained the intestinal barrier integrity by upregulating the production of mucus and the expression of tight junction (TJ) proteins and thus reduced LPS level in liver. Meanwhile, the compound probiotic reduced inflammation level by inhibiting TLR4/NF-κB signaling pathway and suppressed oxidative stress level in liver. Furthermore, the compound probiotic alleviated liver lipid accumulation by regulating fatty acid metabolism-associated genes and AMPK-PPARα signaling pathway. Noteworthy, fecal microbiota transplantation (FMT) realized comparable protective effect with that of compound probiotic. In conclusion, present study demonstrates the beneficial effects and underlying mechanism of the compound probiotic against acute alcohol-induced liver injury. It provides clues for development of novel strategy for treatment of ALD.
Keywords: Alcoholic liver disease; Compound probiotic; Fecal microbiota transplantation; Gut microbiota; Intestinal barrier; Lipopolysaccharide.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Zhou Y, Yuan G, Zhong F, He S (2022) Roles of the complement system in alcohol-induced liver disease. Clin Mol Hepatol 26(4):677–685. https://doi.org/10.3350/cmh.2020.0094 - DOI
-
- Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res 33(6):1627–1638. https://doi.org/10.1002/ptr.6361 - DOI
-
- Federico A, Dallio M, Loguercio C (2017) Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules 22(2):191. https://doi.org/10.3390/molecules22020191 - DOI
-
- Gillessen A, Schmidt HH (2020) Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther 37(4):1279–1301. https://doi.org/10.1007/s12325-020-01251-y - DOI
-
- Chi X, Pan CQ, Liu S, Cheng D, Cao Z, Xing H (2020) Regulating intestinal microbiota in the prevention and treatment of alcohol-related liver disease. Can J Gastroenterol Hepatol 2020:6629196. https://doi.org/10.1155/2020/6629196 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
